Efficacy of CDDP and AGM-1470 Chemotherapy Against Lung Metastasis in Rat Osteosarcoma Depends on the Timing of Combined Administration

Japanese Journal of Clinical Oncology

Volumn 27, Issue 4, 1997, Pages 236-239

  Morishita, Toru ^a,b   Mii, Yoshio ^a   Miyauchi, Yoshizumi ^a   Miura, Shuichi ^a   Honoki, Kanya ^a   Aoki, Makoto ^a   Kido, Akira ^a   Tamai, Susumu ^a   Tsutsumi, Masahiro ^a   Konishi, Yoichi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Departments of Orthopedic Surgery   (Japan)

Author keywords

AGM 1470; CDDP; Combination therapy; Metastasis; Rat osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; CYCLOHEXANE DERIVATIVE; FUMAGILLOL CHLOROACETYLCARBAMATE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANIMAL; ARTICLE; BONE TUMOR; CANCER TRANSPLANTATION; DRUG ADMINISTRATION; FISCHER 344 RAT; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; METASTASIS; OSTEOSARCOMA; PATHOLOGY; RAT; REMISSION; SKIN; SKIN TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; CYCLOHEXANES; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MALE; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; RATS; RATS, INBRED F344; REMISSION INDUCTION; SESQUITERPENES; SKIN; SKIN NEOPLASMS; TIME FACTORS;

EID: 0031205740     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/27.4.236     Document Type: Article

References (23)

1. Holmgren L, O'Reilly SM, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995;1:149-53.
2. Ingber D, Fujita T, Kishimoto S, Katsuichi S, Kanamaru T, Brem H et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
3. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993;53:5233-6.
4. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res 1993;53:4262-7.
5. Morishita T, Mii Y, Miyauchi Y, Miura S, Honoki K, Aoki M et al. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn J Clin Oncol 1995, 25:25-31.
6. Wilson JT, Penar PL. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model. Neurol Res 1994;16:121-4.
7. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, Uchida A. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma Int J Cancer 1995;61:148-52
8. Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470 J Neurosurg 1993;78:470-6
9. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D et al. Potent anti-angiogeneic action of AGM-1470: comparison to the fumagillol parent. Biochem Biophys Res Commun 1991;174:1070-6.
10. Mii Y, Tsutsumi, M, Shiraiwa K, Miyauchi Y, Honoki K, Maruyama H et al. Transplantable osteosarcoma with high lung metastatic potential in Fischer344 rats. Jpn J Cancer Res 1988;79:589-92.
11. Honoki K, Tsutsumi M, Miyauchi Y, Mii Y, Tsujiguchi T, Morishita T et al. Increased expression of nucleoside diphosphate kinase/nm23 and c-Ha-ras mRNA is associated with spontaneous lung metastasis in rat-transplantable osteosarcoma. Cancer Res 1993;53:5038-42.
12. Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, Sommadossi J-P. Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470;AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 1995;55:3036-42.
13. Miura S, Mii Y, Miyauchi Y, Ohgushi H, Morishita T, Honoki K et al. Efficacy of slow-releasing anticancer drug delivery systems on transplantable osteosarcoma in rats. Jpn J Clin Oncol 1995;25:61-71
14. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-6.
15. Kusaka M, Sudo K, Matsunami E, Kozai Y, Marui S, Fujita D et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP470 (AGM-1470). Br J Cancer 1994;69:212-6.
16. Pluda J, Wyvill K, Whitcup S, Lietzau J, Saville M, Cohen R et al. A phase I study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients (PTS) with HIV-associated Kaposi's sarcoma (KS). American Society of Clinicl Oncology Thirtieth Annual Meeting, Dallas, TX, 1994, (Abstract).
17. Nishimura Y, Hiraoka M, Jo S, Akuta K, Yukawa Y, Shibamoto Y et al. Microangiographic and histologic analysis of hyperthermia on murine tumor vasculature. Int J Radiat Oncol Biol Phys 1988;15:411-20.
18. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
19. Folkman J. Tumor angiogenesis factor. Cancer Res 1974;34:2109-13.
20. O'Reilly M, Rosalind R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y, Folkman J. The suppression of tumor metastases by a primary tumor. Surg Forum 1993;44:474-6.
21. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogeneic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52 6702-4.
22. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-7.
23. Nishimura Y, Murata R, Hiraoka M Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996;73:270-4.